TLSA Stock Overview A biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Tiziana Life Sciences Ltd Competitors Price History & Performance
Summary of share price highs, lows and changes for Tiziana Life Sciences Historical stock prices Current Share Price US$0.79 52 Week High US$1.74 52 Week Low US$0.41 Beta 0.25 1 Month Change 17.70% 3 Month Change -19.99% 1 Year Change 42.06% 3 Year Change -1.12% 5 Year Change n/a Change since IPO -47.19%
Recent News & Updates
Tiziana Life Sciences Ltd Announces Positive Results in Treating Spinal Cord Injury with Nasal Anti-Cd3 Jan 24
Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab Jan 23
Tiziana Life Sciences Ltd. Announces Findings on the Prolonged Benefits of its Nasal Anti-CD3 Monoclonal Antibody Jan 13
Tiziana Life Sciences: Awaiting Data Of Foralumab For Secondary Progressive Multiple Sclerosis Dec 24
Tiziana Life Sciences Announces First Patient with Moderate Alzheimer's Disease Dosed with Intranasal Foralumab Dec 18
Tiziana Life Sciences Ltd Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional U.S. Medical Centers Dec 04 See more updates
Tiziana Life Sciences Ltd Announces Positive Results in Treating Spinal Cord Injury with Nasal Anti-Cd3 Jan 24
Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab Jan 23
Tiziana Life Sciences Ltd. Announces Findings on the Prolonged Benefits of its Nasal Anti-CD3 Monoclonal Antibody Jan 13
Tiziana Life Sciences: Awaiting Data Of Foralumab For Secondary Progressive Multiple Sclerosis Dec 24
Tiziana Life Sciences Announces First Patient with Moderate Alzheimer's Disease Dosed with Intranasal Foralumab Dec 18
Tiziana Life Sciences Ltd Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional U.S. Medical Centers Dec 04
New minor risk - Shareholder dilution Dec 03
Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study Oct 31 Tiziana Life Sciences Ltd has filed a Follow-on Equity Offering in the amount of $50 million. Oct 26
New minor risk - Market cap size Sep 04
Tiziana Life Sciences Ltd. Announces Chief Executive Officer Changes Aug 19
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule Aug 14
Insufficient new directors Jul 30
FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis Jun 13
Tiziana Life Sciences, Ltd. Announces Qualitative Results for All 10 Non-Active Secondary Progressive Multiple Sclerosis (Na-Spms) Patients Enrolled in the Intermediate-Size Patient Population Expanded Access (Ea) Program Jun 08 Tiziana Life Sciences Ltd announced delayed 20-F filing May 01
Tiziana Life Sciences, Ltd. Announces FDA Allowance for Additional Twenty Patients to Be Enroll in Intranasal Foralumab Multiple Sclerosis Expanded Access Program Apr 24
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in Its Expanded Access Program Apr 23
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with Pira Highlighted in Neurology Apr 20
New minor risk - Share price stability Apr 19
Tiziana Life Sciences Ltd. Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology Apr 19
Tiziana Life Sciences Ltd. Announces Updated Clinical and Pet Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients Jan 09
Tiziana Life Sciences Ltd Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation Jan 05
Tiziana Life Sciences Ltd. Doses First Patient in Phase 2A Trial of Intranasal Foralumab in Multiple Sclerosis Dec 19
Tiziana Life Sciences Ltd, Annual General Meeting, Dec 14, 2023 Dec 02
Tiziana Life Sciences Ltd. Announces Successfully Enrolled and Dosed Four New Patients with Non-Active Secondary Progressive Multiple Sclerosis Dec 01
New minor risk - Financial data availability Nov 12
Tiziana Life Sciences Ltd. Announces Allowance by Fda for At-Home Dosing of Intranasal Foralumab for Multiple Sclerosis Treatment Oct 19
Tiziana Life Sciences Ltd. Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab Oct 17
Tiziana Announces Positive Qualitative Six-Month Pet Scan Results with Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed with Non-Active Secondary Progressive MS (Na-SPMS) Oct 14
Tiziana Life Sciences Ltd. Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis Sep 27
Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely? Sep 19
Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer, Effective September 1, 2023 Aug 24
New major risk - Share price stability Aug 16
Insufficient new directors Aug 01
Tiziana Life Sciences Ltd Appoints Matthew Davis as Its New Chief Operating Officer Jun 14
New minor risk - Market cap size Jun 08
Tiziana Life Sciences Ltd. Announces Reduction in Microglial Activation in Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis Jun 07
We're Keeping An Eye On Tiziana Life Sciences' (NASDAQ:TLSA) Cash Burn Rate Jun 03
Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely? Jan 16
Tiziana Life Sciences Announces IND Filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung Cancer Jan 05
Tiziana Life Sciences Ltd Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (Spms) After Eleven Months of Dosing with Intranasal Foralumab Jan 04
Tiziana Life Sciences Ltd Announces Completion of Prerequisite Pre-Clinical Safety Study Dec 16
Tiziana Life Sciences Ltd. Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirements Dec 15
Tiziana Life Sciences Ltd, Annual General Meeting, Dec 29, 2022 Dec 07
Tiziana Life Sciences Ltd Announces Publication of A Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T Cell Function and an Induced T Cell Regulatory Response in Human Subjects Nov 24
Less than half of directors are independent Nov 16
Tiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (Cns) Nov 11
Tiziana Life Sciences Completes Enrollment of the First Patient Cohort for Its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients Nov 03
Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in Its Intermediate Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients Oct 27
Tiziana Life Sciences Ltd. Plans to Submit IND for Phase 1 Trial of Intranasal Foralumab in Alzheimer's Disease Patients Oct 13
Tiziana Life rises 11% after submitting application to begin human trial of Alzheimer's intranasal therapy Oct 12
Tiziana chief medical officer further increases holdings in company Sep 23
Tiziana Life Sciences Ltd Announces Continued Clinical Improvements in the Second Patient with Secondary Progressive Multiple Sclerosis (Spms) After Six Months of Dosing with Intranasal Foralumab Sep 21
Tiziana Life Sciences Ltd(NasdaqGM:TLSA) dropped from S&P Global BMI Index Sep 19
Tiziana Life Sciences Announces Grant Received by the Brigham and Women’S Hospital to Explore the Use of Intranasal Anti-Cd3 Mab in Amyotrophic Lateral Sclerosis Sep 16
Tiziana Life Sciences executive chairman further raises stake in company Sep 16
Tiziana executive chairman raises stake in company again, buys more shares Aug 25
Tiziana Life Sciences discloses share purchase by executive chairman Aug 17
Is Tiziana Life Sciences (NASDAQ:TLSA) In A Good Position To Deliver On Growth Plans? Aug 15
Less than half of directors are independent Jul 29
Tiziana Life Sciences Appoints Matthew W. Davis as Chief Medical Officer and Acting Chief Scientific Officer Jul 19 Tiziana Life Sciences Ltd Announces Resignation of Kunwar Shailubhai as Chief Scientific Officer and Board Director
Tiziana Life Sciences CEO Kunwar Shailubhai resigns Jul 15
Tiziana Life Sciences Receives Nasdaq Deficiency Notice Jun 20
Tiziana Life Sciences Announces Positive Clinical Results in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab Jun 09
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Rules May 26
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Rules May 25
Less than half of directors are independent Apr 27
Tiziana Life Sciences Announces FDA Grants Permission to Enroll Up to 8 Additional Secondary Progressive Multiple Sclerosis Patients in the Expanded Access Program with Intranasal Foralumab Apr 06
Tiziana Life Sciences Ltd Announces Submission of Amendment to Investigational New Drug Application to Advance Oral Foralumab, Fully Human Anti-Cd3 Monoclonal Antibody, in Patients with Crohn’s Disease Feb 05
Tiziana Life Sciences PLC (NasdaqGM:TLSA) announces an Equity Buyback for $5 million worth of its shares. Jan 25
Tiziana Life Sciences PLC Enrolls Second Patient in Ongoing Intranasal Foralumab Evaluation for Secondary Progressive Multiple Sclerosis Jan 12
Less than half of directors are independent Oct 23 Shareholder Returns TLSA US Biotechs US Market 7D 7.1% 3.6% 1.8% 1Y 42.1% -3.7% 24.9%
See full shareholder returns
Return vs Market: TLSA exceeded the US Market which returned 24.9% over the past year.
Price Volatility Is TLSA's price volatile compared to industry and market? TLSA volatility TLSA Average Weekly Movement 14.9% Biotechs Industry Average Movement 11.3% Market Average Movement 6.5% 10% most volatile stocks in US Market 18.9% 10% least volatile stocks in US Market 3.2%
Stable Share Price: TLSA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TLSA's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States. The company’s lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications.
Show more Tiziana Life Sciences Ltd Fundamentals Summary How do Tiziana Life Sciences's earnings and revenue compare to its market cap? TLSA fundamental statistics Market cap US$86.41m Earnings (TTM ) -US$13.73m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) TLSA income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$13.73m Earnings -US$13.73m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/26 11:59 End of Day Share Price 2025/01/24 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Tiziana Life Sciences Ltd is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Mayank Mamtani B. Riley Securities, Inc. Robin Campbell Equity Development Limited Raghuram Selvaraju H.C. Wainwright & Co.
Show 3 more analysts 
